Is Otosclerosis Genetic? Causes and Hereditary Factors

Otosclerosis has a strong genetic component, with most family-based studies pointing to an inherited pattern that runs through generations. Roughly half of people diagnosed with clinical otosclerosis report a family history of the condition, and the prevailing view among researchers is that it follows a dominant inheritance pattern, though one with a twist: carrying the relevant gene variants does not guarantee you will develop symptoms. That incomplete link between genes and disease is a big part of why otosclerosis can seem to skip generations or appear out of nowhere, and it is also why the search for specific causal genes has been slower and messier than researchers once hoped.

How Otosclerosis Runs in Families

Most studies of families affected by otosclerosis describe an autosomal dominant mode of inheritance with reduced penetrance of about 40%.¹ In plain terms, “autosomal dominant” means you only need to inherit a faulty copy of the gene from one parent, not both. But “reduced penetrance” is the critical caveat: even if you carry the gene variant, there is only about a four-in-ten chance you will actually develop the disease. The rest of the carriers never show symptoms.

This is why otosclerosis can look unpredictable in a family tree. A grandparent might have had hearing loss, both parents seem fine, and then a grandchild is diagnosed in their thirties. The gene was likely passed down through one of the unaffected parents who carried the variant silently. Significant genetic heterogeneity also complicates matters: different families may carry variants in entirely different genes, all leading to the same clinical picture of abnormal bone growth in the ear.²

The Search for Specific Genes

Researchers have mapped several chromosomal regions linked to otosclerosis in large affected families. These are labeled OTSC1 through OTSC10, each sitting on a different stretch of DNA. The first locus identified, OTSC1, is on chromosome 15. A second locus, OTSC2, was mapped to a region on chromosome 7.³ A fourth locus, OTSC4, landed on chromosome 16, in an interval that includes genes involved in immune function and bone regulation.⁴ Despite all this mapping, no single “otosclerosis gene” has been pinned down with certainty. Each locus highlights a neighborhood of the genome rather than a specific address.

Beyond the family-based linkage studies, genome-wide analyses in larger populations have flagged individual genes with strong statistical associations. The most replicated finding involves a gene called RELN, located on chromosome 7. A genome-wide analysis first identified variants within RELN as strongly associated with otosclerosis.⁵ That association was then confirmed across multiple European populations.⁶ More recently, a meta-analysis pooling data across different ethnic groups found the link held up broadly, with a particular variant showing a protective effect against the disease.⁷

RELN is best known for its role in brain development, which makes its involvement in an ear-bone disorder surprising. The protein it encodes, reelin, influences how cells move and organize during development. Researchers suspect it may also play a role in how the tiny bones of the middle ear maintain themselves over time, though the exact mechanism is still being worked out.

Another gene of interest is COL1A1, which codes for part of type I collagen, the main structural protein in bone. A meta-analysis found a significant association between COL1A1 variants and otosclerosis, though the researchers noted that the effect sizes reported in earlier studies were likely inflated.⁸ The COL1A1 connection is interesting because mutations in the same gene can also cause osteogenesis imperfecta, a condition with overlapping features in the ear.

What Goes Wrong in the Ear

To understand why genetics matters here, it helps to know what otosclerosis actually does. The inner ear is encased in a shell of bone called the otic capsule, and under normal circumstances this bone is remarkably stable compared to bone elsewhere in the body. In otosclerosis, patches of the otic capsule begin abnormal remodeling: old bone is chewed away by cells called osteoclasts and replaced by softer, spongy new bone. When this process reaches the stapes, the smallest bone in the middle ear, it can lock the stapes in place and prevent it from vibrating properly. The result is conductive hearing loss, the type caused by a mechanical blockage rather than nerve damage.

Evidence from animal models supports the idea that genetic disruption of bone-maintenance signals can reproduce this process. Mice lacking the gene for osteoprotegerin, a protein that normally restrains bone-resorbing cells, developed abnormal remodeling in the otic capsule that closely resembled human otosclerosis.⁹ In humans, the otic capsule is normally resistant to the kind of active bone turnover seen elsewhere in the skeleton, and the breakdown of that resistance appears to be central to the disease.¹⁰

Additional molecular work has shown that a growth factor called TGF-beta 1 is expressed at abnormally high levels in the diseased stapes bone of otosclerosis patients compared to controls.¹¹ TGF-beta 1 is a powerful regulator of bone formation and immune signaling, and its overactivity could help explain why the bone-remodeling process in otosclerosis is so hard to shut off once it starts.

Beyond DNA Sequence Changes

Not all genetic influence operates through the DNA sequence you were born with. Epigenetic changes, which alter how genes are read without changing the underlying code, are also under investigation. One study found that global DNA methylation levels were roughly four to five times lower in otosclerosis patients than in controls, and that these methylation changes occurred around a gene called TNFSF11 (also known as RANKL), which is a key driver of osteoclast activity and bone resorption.¹² Lower methylation around TNFSF11 could mean the gene is more active than it should be, potentially tipping the balance toward excessive bone breakdown.

Researchers have also looked at small regulatory molecules called microRNAs in the perilymph (the fluid inside the inner ear) of otosclerosis patients. Hundreds of these microRNAs were found to be active, many of them regulating genes involved in bone growth and turnover.¹³ This line of work is still early, but it suggests that the disease process involves a broad disturbance in how bone-related genes are regulated, not just a single broken gene.

The Measles Virus Debate

One of the most persistent non-genetic theories about otosclerosis involves the measles virus. Several research groups have detected measles virus RNA in the stapes bone of otosclerosis patients but not in healthy controls, leading some to conclude that a lingering measles infection might trigger or worsen the disease in genetically susceptible people.¹⁴ The idea has been supported by the observation that otosclerosis rates have declined in countries with widespread measles vaccination programs.¹⁵

But the evidence is genuinely contradictory. A Japanese study using rigorous laboratory methods found no trace of measles virus in bone samples, primary cell cultures, or even measles-susceptible cell lines exposed to otosclerotic tissue.¹⁶ The most honest summary is that measles may be an environmental trigger in some populations, but it is neither necessary nor sufficient to cause the disease on its own. Genetics loads the gun; whether measles pulls the trigger remains an open question.

Pregnancy, Hormones, and the Female Skew

Otosclerosis is diagnosed roughly 1.5 to 2 times more often in women than in men.¹⁷ For decades, this was attributed to hormonal effects, particularly the surge of estrogen during pregnancy. Clinicians often warned women with otosclerosis that pregnancy could accelerate their hearing loss. The clinical observation behind this was straightforward: women with children tended to need stapes surgery at a younger age than childless women. One large study confirmed this, finding a significant gap of roughly ten years in the average age at surgery between mothers and non-mothers.¹⁸

However, a more careful look at the data complicates the story. The same pattern held for men with and without children: fathers had surgery about ten years earlier than childless men, too. That finding is hard to explain with estrogen alone. And a separate case-control study of nearly 1,200 women found no significant association between number of deliveries and the odds of developing otosclerosis. Neither did prior removal of both ovaries, which drastically reduces estrogen levels, seem to protect against the disease.¹⁹ The female predominance is real, but its explanation may lie somewhere other than pregnancy hormones. It could reflect differences in how men and women seek medical care, sex-linked differences in otic capsule biology, or interactions between sex hormones and genetic susceptibility that are more subtle than a direct estrogen effect.

Who Gets Otosclerosis

Most people are diagnosed in their thirties or forties, with onset before age 10 or after age 50 being uncommon.¹⁷ A population-based study covering 70 years of data found a median age at diagnosis of 42 years, with incidence remaining fairly constant across the decades studied.²⁰

For a long time, otosclerosis was considered primarily a disease of white populations. More recent data suggests that picture was incomplete. Between 2000 and 2017, the incidence rate was roughly 5 to 6 per 100,000 person-years across white, Black, Asian, and Hispanic groups, with the proportion of non-white cases increasing significantly over the study period.²⁰ Whether earlier estimates of racial disparity reflected true biological differences or simply unequal access to diagnosis is unclear, but the gap has narrowed considerably.

Histologic Versus Clinical Disease

One of the stranger facts about otosclerosis is that far more people have it than know about it. Temporal bone studies on cadavers have found histological evidence of otosclerosis in roughly 8% to 12% of the general population, but only about 12% to 15% of those histologic cases show actual fixation of the stapes.²¹ Working backward from those numbers gives an estimated clinical prevalence of about 1%, yet clinical surveys based on family data suggest only about 0.3% of the population is actually diagnosed. This means most otosclerotic bone changes never progress to the point of causing noticeable hearing loss.

This gap has real implications for understanding the genetics. The genes that predispose someone to abnormal otic capsule remodeling may be relatively common, but additional factors, whether other genes, environmental exposures, or epigenetic switches, seem to determine whether the process progresses far enough to fix the stapes and cause symptoms. It is a useful reminder that inheriting “the gene” for otosclerosis, whatever that turns out to mean in full, does not automatically lead to hearing loss.

Overlap With Osteogenesis Imperfecta

Osteogenesis imperfecta, often called brittle bone disease, can produce hearing loss that looks remarkably similar to otosclerosis on an audiogram. Both conditions involve abnormal bone remodeling in the otic capsule. However, the pattern on CT imaging tends to differ: otic capsule demineralization shows up more frequently and in more locations in osteogenesis imperfecta than in otosclerosis, and the degree of conductive hearing loss is typically greater in otosclerosis patients.²² Both conditions share links to type I collagen genes, which helps explain the overlap, but they are genetically distinct in most cases. For anyone with a family history of brittle bones and hearing loss, the distinction matters because it can affect treatment decisions.

Treatment and What Genetics Might Change

The standard treatment for otosclerosis that causes significant conductive hearing loss is stapes surgery, where the fixed stapes bone is partially or fully replaced with a tiny prosthesis. Hearing aids are the other main option. But when the disease also involves the inner ear, causing sensorineural hearing loss on top of the conductive component, surgery cannot fix the nerve-related portion.

For those sensorineural cases, medications that slow bone turnover have been tried. Sodium fluoride has the longest track record: administered for at least six months, it appears to stabilize hearing thresholds and may help with vestibular symptoms and tinnitus.²³ Bisphosphonates, drugs widely used for osteoporosis, have also been explored. A scoping review found that bisphosphonates may stabilize future hearing loss in patients with sensorineural involvement, though actual improvement in hearing is unlikely, and the overall evidence remains inconclusive.²⁴

Understanding the genetic architecture of otosclerosis could eventually change this picture. If specific molecular pathways can be tied to disease progression, targeted therapies that intervene earlier and more precisely become at least theoretically possible. The discovery of elevated TGF-beta 1 in otosclerotic bone and the identification of active microRNA pathways in the inner ear fluid both point toward potential drug targets. But translating these molecular clues into approved treatments is a long road, and no gene-based therapy for otosclerosis is anywhere close to clinical use.

Genetic Counseling for Affected Families

If you have otosclerosis and are wondering about the risk to your children, the math is not especially reassuring but also not catastrophic. Under a dominant model with roughly 40% penetrance, each child of an affected parent has about a 50% chance of inheriting the risk variant and then about a 40% chance of that variant actually producing clinical disease. That works out to about a one-in-five chance per child. In practice, the numbers are rougher than that because multiple genes contribute and environmental factors play a role, but one in five is a reasonable ballpark.

Genetic testing for otosclerosis is not currently part of routine clinical care. No panel of genes is validated well enough to tell an individual whether they will develop the condition or how severe it will be. The genetic heterogeneity, meaning different families carry different causative variants, makes a single diagnostic test impractical with current knowledge.² What a family history can do is prompt earlier hearing screening. If a parent or grandparent had otosclerosis, catching subtle hearing changes in the next generation while the disease is still early may open the door to monitoring and earlier intervention rather than a diagnosis that arrives only after significant hearing loss has set in.